Research programme: osteoporosis therapy - Tanox/ Wyeth

Drug Profile

Research programme: osteoporosis therapy - Tanox/ Wyeth

Alternative Names: Anti secreted apoptosis-related protein 2 monoclonal antibody; Anti-SARP2 humanised monoclonal antibody; Humanised anti-SARP2 monoclonal antibody; TNX-717

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator Tanox; Wyeth
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Osteoblast stimulants; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Fracture; Osteoporosis

Most Recent Events

  • 03 Aug 2007 Tanox has been acquired by Genentech
  • 04 May 2007 Preclinical development is ongoing
  • 12 Jan 2005 Preclinical trials in Fracture treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top